Top 10 Drugs by Worldwide Sales in 2025

The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025.

Top 10 Drugs by Worldwide Sales in 2025

Highlights and Market Trends

Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year (257) .

GLP-1 receptor agonists dominate the metabolic therapy segment with four drugs in the top 10: Ozempic and Wegovy (both semaglutide-based), Mounjaro and Zepbound (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic diseases (25).



Dupixent (dupilumab) and Skyrizi (risankizumab) are prominent autoimmune therapies, addressing conditions like atopic dermatitis, asthma, psoriasis, and Crohn’s disease, maintaining strong market positions with combined sales near $30 billion (25).

Eliquis (apixaban), an anticoagulant, continues to be a top seller due to its widespread use in stroke prevention for atrial fibrillation and treatment of thromboembolic disorders (35).

HIV treatment Biktarvy and cancer drug Darzalex also maintain high sales, each expected around $13 billion, underscoring continued demand in infectious disease and oncology (5).

Conclusion

The 2025 pharmaceutical sales landscape is led by innovative immunotherapies and metabolic drugs that address some of the largest global health burdens—cancer, diabetes, obesity, and autoimmune diseases. Merck’s Keytruda solidifies its position as the top-selling drug worldwide, while Novo Nordisk and Eli Lilly capture significant market shares in metabolic therapies. The sustained success of these drugs highlights the pharmaceutical industry's focus on chronic and complex diseases with high unmet medical needs (257).

Comments

Pages

Popular posts from this blog

Top 10 Drugs by Worldwide Sales in 2024

Top 10 Pharmaceutical Companies by Revenue in 2025

7 Best Crypto Exchanges Malaysia 2025

5 Top Silver ETFs 2025: What You Need to Know

Top 10 Pharma Companies by R&D Spend 2024

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies 2025

Pharma & Cancer Treatment 2025: Breakthroughs, Market Leaders, and Industry Trends

10 Best E Wallets in Malaysia 2025

12 Best SME Business Loans in Malaysia 2025